Cantor Fitzgerald Analysts Lower Earnings Estimates for Aerie Pharmaceuticals, Inc. (AERI)
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Analysts at Cantor Fitzgerald dropped their FY2018 earnings per share estimates for shares of Aerie Pharmaceuticals in a research note issued to investors on Monday. Cantor Fitzgerald analyst E. Piros now anticipates that the company will post earnings of ($2.97) per share for the year, down from their previous estimate of ($2.17). Cantor Fitzgerald currently has a “Buy” rating and a $69.00 target price on the stock.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/cantor-fitzgerald-analysts-lower-earnings-estimates-for-aerie-pharmaceuticals-inc-aeri/1722443.html.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Canaccord Genuity reiterated a “positive” rating and issued a $73.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Needham & Company LLC reiterated a “buy” rating and issued a $76.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Cowen and Company reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. Finally, JMP Securities set a $68.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average price target of $71.43.
Shares of Aerie Pharmaceuticals (AERI) traded up $0.15 on Wednesday, hitting $61.55. 188,700 shares of the stock were exchanged, compared to its average volume of 520,614. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 1-year low of $35.20 and a 1-year high of $66.25.
A number of hedge funds and other institutional investors have recently modified their holdings of AERI. Teachers Advisors LLC grew its stake in Aerie Pharmaceuticals by 5.1% in the 1st quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock valued at $2,255,000 after acquiring an additional 2,402 shares during the last quarter. California Public Employees Retirement System acquired a new stake in Aerie Pharmaceuticals in the 1st quarter valued at about $231,000. Vanguard Group Inc. grew its stake in Aerie Pharmaceuticals by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock valued at $63,151,000 after acquiring an additional 92,463 shares during the last quarter. Geode Capital Management LLC grew its stake in Aerie Pharmaceuticals by 3.3% in the 1st quarter. Geode Capital Management LLC now owns 262,221 shares of the company’s stock valued at $11,891,000 after acquiring an additional 8,365 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Aerie Pharmaceuticals by 113,376.8% in the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after acquiring an additional 2,598,596 shares during the last quarter.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.